Abstract
Pituitary adenylate cyclase activating polypeptide (PACAP) is a ubiquitous neuropeptide in the central and peripheral nervous systems. PACAP is also produced by pancreatic islet cells. PACAP regulates the glucose and energy metabolism at multiple processes in several tissues. At postprandial states, PACAP potentiates both insulin release from pancreatic β-cells and insulin action in adipocytes, contributing to energy storage. At fasting states, PACAP on the one hand promotes feeding behavior by activating neuropeptide Y neurons in the hypothalamic feeding center, arcuate nucleus, and on the other hand stimulates secretion of catecholamine and glucagon and thereby induces lipolysis in adipocytes and glucose output from liver. Thus, PACAP plays an integrative role in the glucose and energy homeostasis. Dysfunction of expression, secretion and/or action of PACAP might be involved in the type 2 diabetes and metabolic syndrome. PACAP receptor subtype-specific agonists and/or antagonists are hopeful therapeutic agents.
Keywords: VPAC2-R-deficient mice, PACAP receptors, Adipocytes, Lipolysis, Catecholamines
Current Pharmaceutical Design
Title: PACAP in the Glucose and Energy Homeostasis: Physiological Role and Therapeutic Potential
Volume: 13 Issue: 11
Author(s): Masanori Nakata and Toshihiko Yada
Affiliation:
Keywords: VPAC2-R-deficient mice, PACAP receptors, Adipocytes, Lipolysis, Catecholamines
Abstract: Pituitary adenylate cyclase activating polypeptide (PACAP) is a ubiquitous neuropeptide in the central and peripheral nervous systems. PACAP is also produced by pancreatic islet cells. PACAP regulates the glucose and energy metabolism at multiple processes in several tissues. At postprandial states, PACAP potentiates both insulin release from pancreatic β-cells and insulin action in adipocytes, contributing to energy storage. At fasting states, PACAP on the one hand promotes feeding behavior by activating neuropeptide Y neurons in the hypothalamic feeding center, arcuate nucleus, and on the other hand stimulates secretion of catecholamine and glucagon and thereby induces lipolysis in adipocytes and glucose output from liver. Thus, PACAP plays an integrative role in the glucose and energy homeostasis. Dysfunction of expression, secretion and/or action of PACAP might be involved in the type 2 diabetes and metabolic syndrome. PACAP receptor subtype-specific agonists and/or antagonists are hopeful therapeutic agents.
Export Options
About this article
Cite this article as:
Nakata Masanori and Yada Toshihiko, PACAP in the Glucose and Energy Homeostasis: Physiological Role and Therapeutic Potential, Current Pharmaceutical Design 2007; 13 (11) . https://dx.doi.org/10.2174/138161207780618948
DOI https://dx.doi.org/10.2174/138161207780618948 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Para-Tyrosine Supplementation Improves Insulin- and Liraglutide- Induced Vasorelaxation in Cholesterol-Fed Rats
Protein & Peptide Letters Synopsis on Managment Strategies for Neurodegenerative Disorders: Challenges from Bench to Bedside in Successful Drug Discovery and Development
Current Topics in Medicinal Chemistry Hypothalamic AMP-activated Protein Kinase as a Regulator of Food Intake and Energy Balance
CNS & Neurological Disorders - Drug Targets Effect of Diabetes on The Blood Brain Barrier
Current Pharmaceutical Design High-Sensitivity C-Reactive Protein and Lipoprotein-Associated Phospholipase A2 in Predicting Recurrence and Severity of Stenosis in Symptomatic Intracranial Atherosclerotic Disease
Current Proteomics Hydroxysteroid Dehydrogenase (17β -HSD3, 17β-HSD5, and 3α-HSD3) Inhibitors:Extragonadal Regulation of Intracellular Sex Steroid Hormone Levels
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) The Pathophysiological Basis of Carotid Baroreceptor Stimulation for the Treatment of Resistant Hypertension
Current Vascular Pharmacology La(NO<sub>3</sub>)<sub>3</sub>.6H<sub>2</sub>O Catalyzed One-pot Highly Diastereoselective Synthesis of Functionalized Piperidines
Letters in Organic Chemistry Influence of Passion Fruit (Passiflora edulis, f. flavicarpa, DEG) Juice Sweetened with Sucrose, Saccharin and Cyclamate on Blood Glucose in Normal and Diabetic Rats (Rattus norvegicus)
The Natural Products Journal In Silico Study of Flavonoids as DPP-4 and α-glucosidase Inhibitors
Letters in Drug Design & Discovery Dissolution Rate Enhancement of Repaglinide Using Dietary Fiber as a Promising Carrier
Current Drug Delivery Agonism of Peroxisome Proliferator Receptor-Gamma may have Therapeutic Potential for Neuroinflammation and Parkinsons Disease
Current Neuropharmacology Effects of Mesenchymal Stromal Cells on Diabetic Cardiomyopathy
Current Pharmaceutical Design Genetics and Genomics of Hepatic Acute Phase Reactants: A Mini-Review
Inflammation & Allergy - Drug Targets (Discontinued) Pioglitazone and Rosiglitazone: Effects of Treatment with a Thiazolidinedione on Lipids and Non Conventional Cardiovascular Risk Factors
Current Clinical Pharmacology Meet Our Editorial Board Member
Endocrine, Metabolic & Immune Disorders - Drug Targets Insights into the Role of DNA Methylation and Protein Misfolding in Diabetes Mellitus
Endocrine, Metabolic & Immune Disorders - Drug Targets Dietary Transition in the South Asian Diaspora: Implications for Diabetes Prevention Strategies
Current Diabetes Reviews SGLT-2 Inhibitors: Ideal Remedy for Cardioprotection in Diabetes Mellitus
Current Molecular Pharmacology Marine Food Protection in Testicular Damages Caused by Diabetes Mellitus
Current Diabetes Reviews